37 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
for various reasons, including noncompliance with regulatory requirements or safety concerns, among others;
lower than anticipated retention rates … recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement business strategy, which could harm our business
F-3
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
circumstances, the board of directors may be paid variable compensation, depending on the achievement of certain performance criteria or for retention
F-3
EX-4.1
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
strategic and/or financial objectives, as well as retention elements.
Le conseil d’administration, le comité de rémunération ou tout autre organe
F-3
EX-4.1
5ob52r l6
17 Feb 22
Shelf registration (foreign)
4:14pm
6-K
EX-99.3
dby5ybfh730yvt
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K/A
EX-99.2
4djzkw
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.2
buu m3fsw5bbcloxj
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-1.1
w0y3r2ac2
5 Mar 21
Current report (foreign)
8:15am
424B5
gm54nza6zd9n40
5 Mar 21
Prospectus supplement for primary offering
7:55am
6-K
EX-1.1
gg7elyxg1j2
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
eh4tvrlu1
8 Sep 20
Prospectus supplement for primary offering
7:31am
F-3
EX-4.1
0mke9jtjy8ot1b60xx
7 Aug 19
Shelf registration (foreign)
8:24am
F-3
g0091ckm
7 Aug 19
Shelf registration (foreign)
8:24am
424B5
l56y879
7 Aug 19
Prospectus supplement for primary offering
8:18am